Zydus Lifesciences Makes 4 Global Acquisitions in 1 Year; What’s Going On with the Pharma Stock?

Synopsis: Zydus Lifesciences is expanding globally through selective acquisitions across biologics, MedTech, and specialty pharma, supported by a ₹88,297 crore market cap, 118.8% five-year returns, and a growing focus beyond US generics.

Zydus Lifesciences has remained in focus as it continues to pursue acquisitions across international healthcare markets, expanding its footprint beyond India. The company’s steady deal-making activity, spanning pharmaceuticals and related healthcare segments, has drawn attention from investors and industry observers amid a rapidly consolidating global healthcare landscape.

Zydus Lifesciences Limited, with a market capitalization of Rs. 89,439.11 crore, is trading at Rs. 888.95 per equity share, up by 0.09 percent from its previous day’s close price of Rs. 888.15 per equity share.

Zydus Lifesciences Limited has delivered returns across multiple timeframes, with a 1-month return of 0.12 percent, a 3-month return of -6.21 percent, and a 6-month return of -5.61 percent The stock has delivered a -10.83 percent return in the past 1 year and in the longer frame of 5 years it has delivered a return of 87.34 percent.

Zydus Lifesciences Limited, founded in 1952 and headquartered in Ahmedabad, operates globally across pharmaceuticals and consumer healthcare. It develops and markets APIs, generics, biosimilars, vaccines, specialty and wellness products, with a strong pipeline across oncology, autoimmune, metabolic, and infectious disease therapies.

Sterling Biotech (India)

In August 2024, Zydus Lifesciences acquired a 50 percent stake in Sterling Biotech, forming a joint venture focused on fermentation-based APIs and biotechnology. This acquisition strengthened Zydus’s presence in complex and high-entry-barrier manufacturing, particularly in fermentation-derived products where global supply is limited and regulatory standards are stringent. 

The JV provides Zydus with scalable capabilities in niche APIs, supporting both captive requirements and export-led growth, while improving vertical integration and long-term cost competitiveness.

Agenus Biologics Facilities (USA)

In June 2025, Zydus signed an agreement to acquire biologics manufacturing facilities from Agenus Inc. in California, with transaction closure expected in January 2026. The deal involved an upfront payment of $75 million along with contingent payments and marked Zydus’s formal entry into biologics CDMO manufacturing in the US. 

The acquisition gives Zydus immediate access to advanced biologics infrastructure in a key biotech hub, enabling end-to-end services from pre-clinical to commercial manufacturing and positioning the company to tap into the fast-growing global biologics CDMO market.

Amplitude Surgical (France)

Zydus acquired a 100 percent stake in France-based Amplitude Surgical through a phased transaction that began in March 2025 and was completed by October 2025, at a total cost of about €300 million. Amplitude Surgical is a well-established orthopaedic device company with strong R&D, patented technologies, and a global distribution footprint across Europe, Latin America, Asia-Pacific, and Africa. 

This acquisition marked Zydus’s entry into the MedTech space and created a platform to scale its focus areas of orthopaedics, cardiology, and nephrology in regulated international markets.

Proposed Ardelyx Inc. (USA)

In January 2026, Zydus Lifesciences began evaluating the acquisition of a majority stake in US-based biopharmaceutical company Ardelyx Inc., with the deal valued at $2.2–2.5 billion. Ardelyx focuses on first-in-class small-molecule drugs for gastrointestinal and cardio-renal diseases and reported 2025 revenue of $378 million, up 18 percent year-on-year, with a market capitalization of about $1.7 billion. If concluded, this would be Zydus’s largest acquisition and a major step toward building a meaningful specialty and innovation-driven presence in the US market.

Why Is Zydus Acquiring International Companies?

Transition from Generics to Innovation-Led Growth

Zydus’s acquisition strategy reflects a deliberate shift away from commoditised generics toward innovation, speciality products, and branded businesses with stronger pricing power. Persistent pricing pressure in the US generics market has limited growth opportunities, prompting Zydus to acquire companies with differentiated pipelines, first-in-class therapies, and complex manufacturing capabilities. Assets like Ardelyx and Amplitude Surgical directly support this transition by adding innovation-led and technology-driven revenue streams.

Faster and De-Risked Global Expansion

Acquisitions allow Zydus to enter regulated markets such as the US and Europe at scale and speed, bypassing long gestation periods associated with organic expansion. By acquiring established facilities, brands, and commercial infrastructure, Zydus reduces execution risk while gaining immediate market access. The Agenus biologics facilities and Amplitude Surgical’s European footprint are clear examples of how Zydus is using inorganic growth to fast-track its global ambitions.

Diversification

Through targeted acquisitions, Zydus has diversified across multiple therapeutic areas including GI, cardio-renal, orthopaedics, oncology, biologics, vaccines, and consumer wellness. This diversification reduces dependence on any single product, therapy, or geography and creates a more resilient business model. It also aligns with the company’s strategy to build a balanced portfolio spanning pharmaceuticals, MedTech, biologics, and wellness.

Strengthening R&D, Manufacturing, and Technology Capabilities

Zydus is using acquisitions to complement its in-house R&D and manufacturing strengths with advanced technologies and late-stage assets. Biologics manufacturing from Agenus, patented MedTech solutions from Amplitude, and Ardelyx’s innovation pipeline enhance Zydus’s ability to move up the value chain. These capabilities improve returns on R&D investments, accelerate commercialization, and create long-term competitive advantages.

Revenue and Margin Expansion

The ultimate objective of Zydus’s acquisition-led strategy is sustainable growth in revenues and profitability. High-margin segments such as specialty pharma, biologics CDMO, MedTech, and consumer wellness offer better margin profiles than traditional generics. This is already reflected in Zydus’s strong Q2 FY26 performance, with revenue growth of around 17 percent year-on-year and net profit growth of nearly 38 percent, supported by operating leverage and a richer business mix. By continuously acquiring differentiated global assets, Zydus is positioning itself for durable, innovation-driven growth over the long term.

Financial Highlights

The company reported Q2FY26 revenue of Rs. 6,123 crore, delivering a solid 16.9 percent YoY growth over Rs. 5,237 crore in Q2FY25, reflecting strong underlying demand and scale benefits. However, on a sequential basis, revenue declined 6.9 percent QoQ from Rs. 6,574 crore in Q1FY26, indicating a moderation after a strong first quarter.

EBITDA for Q2FY26 stood at Rs. 2,016 crore, registering a robust 38.0 percent YoY growth compared to Rs. 1,461 crore in Q2FY25, while declining 3.4 percent QoQ from Rs. 2,088 crore in Q1FY26. Profit after tax came in at Rs. 1,239 crore, up 34.7 percent YoY from Rs. 920 crore, but fell 18.5 percent QoQ from Rs. 1,521 crore, suggesting margin pressure or higher costs impacting sequential profitability despite strong annual growth.

Over the past five years, the company has demonstrated strong growth, achieving a revenue CAGR of 10 percent, a profit CAGR of 26 percent and a price CAGR of 13 percent, reflecting both its operational performance and market confidence.

A return on equity (ROE) of about 21.2 percent and a return on capital employed (ROCE) of about 17.6 percent, and debt to equity ratio at 0.38 demonstrate the company’s financial position. The stock is currently trading at a P/E of 17.8x lower as compared to industry P/E of 29.4x.

Conclusion

Zydus Lifesciences Limited’s steady pace of international acquisitions reflects a well-calibrated strategy to move up the value chain and reduce dependence on commoditised generics. By selectively adding innovation-led assets, advanced manufacturing capabilities, and exposure to regulated global markets, the company is building a more diversified and resilient business model. While near-term stock performance has been volatile, Zydus’s disciplined inorganic growth approach positions it favourably for sustainable, margin-accretive growth over the long term.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Zydus Lifesciences Makes 4 Global Acquisitions in 1 Year; What’s Going On with the Pharma Stock? appeared first on Trade Brains.